Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Page 1

	Year	Citations
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Andreas Hochhaus, Richard A. Larson, François Guilhot, New England Journal of Medicine	2017	1.2K
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke, Nature Molecular PharmacologyDrug TargetMedicineImmunologyAllosteric Inhibitor Abl001	2017	574
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Blood	2018	572
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, New England Journal of Medicine	2019	449
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud, Leukemia	2020	82
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy Amr R. Ibrahim, Christos Paliompeis, Marco Bua, Blood	2010	72
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i> Laura N Eadie, Verity A Saunders, Susan Branford, Oncotarget	2018	57

Page 1